Skip to main content Accessibility help
×
Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T03:53:21.871Z Has data issue: false hasContentIssue false

Chapter 16 - Medications

Published online by Cambridge University Press:  21 June 2019

Rob Butler
Affiliation:
Waitemata DHB and North Shore Hospital, Auckland
Cornelius Katona
Affiliation:
Helen Bamber Foundation
Get access

Summary

This chapter outlines the pharmacological treatment options available for older adults and covers treatment for cognitive and non-cognitive symptoms of the dementias, delirium, affective disorders and psychosis, and medication optimisation.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Winter, M. E. (2010) Basic Clinical Pharmaokinetics. Baltimore, MD: Lippincott Williams & Wilkins.Google Scholar
Rang, H. P., Henderson, G., Dale, M. M., Flower, R. J., et al. (2016) Rang and Dale’s Pharmacology International Version. London: Churchill Livingstone, pp. 467–79.Google Scholar
Taylor, D., Paton, C., Kapur, S. (2015) The Maudsley Prescribing Guidelines in Psychiatry. 12th ed. Chichester, UK: Wiley Blackwell.Google Scholar
Routledge, P. A., O’Mahony, M. S., Woodhouse, K. W. (2003) ‘Adverse drug reactions in elderly patients’. Br J Clin Pharmacol 57(2): 121–6.Google Scholar
Katona, C., Livingston, G. (2002) ‘How well do antidepressants work in older people? A systematic review of number needed to treat’. J Affect Disord 69(1–3): 4752.CrossRefGoogle ScholarPubMed
Ferris, S. H. (2003) ‘Evaluation of memantine for the treatment of Alzheimer’s disease’. Expert Opin Pharmacol 4(12): 2305–13.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (2016) ‘Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease: Technology appraisal guidance’ [TA217].Google Scholar
Electronic Medicines Compendium (2018) ‘Summary of product characteristics’ [Online], www.medicines.org.uk/emc/.Google Scholar
Olazarán, J., Valle, D., Serra, J. A., Cano, P., et al. (2013) ‘Psychotropic medications and falls in nursing homes: A cross-sectional study’. J Am Med Dir Assoc 14(3): 213–17.Google Scholar
Marvin, V., et al. (2017) ‘Deprescribing medicines in the acute setting to reduce the risk of falls’. Eur J Hosp Pharm 24(1): 1015.CrossRefGoogle ScholarPubMed
Danysz, W., Parsons, C. G. (2012) ‘Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine – searching for the connections’. Br J Pharmacol 167(2): 324–52.CrossRefGoogle ScholarPubMed
Atri, A., Hendrix, S. B., Pejović, V., Hofbauer, R. K., Edwards, J., et al. (2015) ‘Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: A pooled area under the curve analysis’. Alzheimers Res Ther 7(1): 28.Google Scholar
National Institute for Health and Care Excellence (2018) ‘Dementia: assessment, management and support for people living with dementia and their carers’. NICE guideline [NG97], June, www.nice.org.uk/guidance/ng97.Google Scholar
Fox, C., Crugel, M., Maidment, I., Austed, B. H., et al. (2012) ‘Efficacy of memantine for agitation in Alzheimer’s dementia: A randomised double-blind placebo controlled trial’. PLoS ONE 7(5): e35185.Google Scholar
Howard, R. J., Juszczak, E., Ballard, C. G., Bentham, P., et al. (2007) ‘Donepezil for the treatment of agitation in Alzheimer’s disease’. N Engl J Med 357(14): 1382–92.CrossRefGoogle ScholarPubMed
Porsteinsson, A. P., Drye, L. T., Pollock, B. G., Devanand, D. P., et al. (2014) ‘Effect of citalopram on agitation in Alzheimer disease’. JAMA 311(7): 682.Google Scholar
Jiang, H. Y., Chen, H. Z., Hu, X. J., Yu, Z. H., et al. (2015) ‘Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: A systematic review and meta-analysis’. Clin Gastroenterol Hepatol 13(1): 4250.Google Scholar
Huang, A. R., Mallet, L., Rochefort, C. M., Eguale, T., et al. (2012) ‘Medication-related falls in the elderly’. Drugs Aging 29(5): 359–76.Google Scholar
Richardson, K., Bennett, K., Maidment, I. D., Fox, C., et al. (2015) ‘Use of medications with anticholinergic activity and self-reported injurious falls in older community-dwelling adults’. J Am Geriatr Soc 63(8): 1561–9.CrossRefGoogle ScholarPubMed
Kirby, D., Ames, D. (2001) ‘Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients’. Int J Geriatr Psychiatry 16(5): 484–93.Google Scholar
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., et al. (2004) ‘Rivastigmine for dementia associated with Parkinson’s disease’. N Engl J Med 351(24): 2509–18.Google Scholar
Maidment, I. D., Fox, C., Boustani, M. (2005) ‘A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson’s disease dementia’. Acta Psychiatr Scand 111(6): 403–9.Google Scholar
Menza, M., Marsh, L. (2006) Psychiatric Issues in Parkinson’s Disease. Abingdon, UK: Taylor & Francis.Google Scholar
Rahkonen, T. E., Eloniemi-Sulkava, U., Paanila, S., et al. (2001) ‘Systematic intervention for supporting community care of elderly people after a delerium episode’. Int Psychogeriatr 13: 3749.Google Scholar
Siddiqi, N., House, A. O., Holmes, J. D. (2006) ‘Occurrence and outcome of delirium in medical in-patients: A systematic literature review’. Age Ageing 35(4): 350–64.CrossRefGoogle ScholarPubMed
Kales, H. C., Kim, H. M., Zivin, K., Valenstein, M., et al. (2012) ‘Risk of mortality among individual antipsychotics in patients with dementia’. Am J Psychiatry 169(1): 71–9.Google Scholar
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., et al. (2017) ‘Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology’. J Psychopharmacol 31(2): 147–68.Google Scholar
Banerjee, S. (2009) ‘The use of antipsychotic medication for people with dementia: Time for action’, Department of Health.Google Scholar
Cowen, T., Harrison, P., Burns, P. (2012) Shorter Oxford Textbook of Psychiatry. 6th ed. Oxford: Oxford University Press, pp. 318–19.Google Scholar
Cleare, A., Pariante, C. M., Young, A. H., Anderson, I. M., et al. (2015) ‘Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.’ J Psychopharmacol 29(5): 459525.Google Scholar
Hammerlein, A., Derendorf, H., Lowenthal, D. T. (1998) ‘Pharmacokinetic and pharmacodynamic changes in the elderly’. Clin Pharmacokinet 35(1): 4964.CrossRefGoogle ScholarPubMed
Joint Formulary Committee (2017) British National Formulary. 74th ed. London: BMJ Group and Pharmaceutical Press.Google Scholar
Fox, C., Richardson, K., Maidment, I. D., Savva, G. M., et al. (2011) ‘Anticholinergic medication use and cognitive impairment in the older population: The Medical Research Council Cognitive Function and Ageing Study’. J Am Geriatr Soc 59(8): 1477–83.CrossRefGoogle ScholarPubMed
Milton, J. C., Hill-Smith, I., Jackson, S. H. D. (2008) ‘Prescribing for older people’. BMJ 336(7644): 606–9.Google Scholar
Kripalani, M., Shawcross, J., Reilly, J., Main, J. (2009) ‘Lithium and chronic kidney disease’. BMJ 339: b2452.Google Scholar
Shotbolt, D. A., Samuel, M., Fox, C., David, A. S. (2009) ‘A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease’. Neuropsychiatr Dis Treat 5: 327–32.Google Scholar
National Institute for Health and Care Excellence (2015) ‘Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes’. London: NICE.Google Scholar
Gao, L., Maidment, I., Matthews, F. E., Robinson, L., et al. (2017) ‘Medication usage change in older people (65+) in England over 20 years: Findings from CFAS I and CFAS II’. Age and Ageing 26: 16.Google Scholar
Maidment, I. D., Aston, L., Moutela, T., Fox, C. G., et al. (2017) ‘A qualitative study exploring medication management in people with dementia living in the community and the potential role of the community pharmacist’. Health Expect 20(5): 929–42.Google Scholar
Maidment, I. D., Haw, C., Stubbs, J., Fox, C., et al. (2008) ‘Medication errors in older people with mental health problems: A review’. Int J Geriatr Psychiatry 23(6): 564–73.Google Scholar
Pirmohamed, M. (2004) ‘Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients’. BMJ 329(7456): 1519.Google Scholar
National Institute for Health and Care Excellence (2009) ‘Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence’. London: NICE.Google Scholar
Maidment, I. D. (2013) ‘Medication-related adverse events in older people with dementia causes and possible solutions’ (PhD diss., Aston University).Google Scholar
Aston, L., Hilton, A., Moutela, T., Shaw, R., et al. (2017) ‘Exploring the evidence base for how people with dementia and their informal carers manage their medication in the community: A mixed studies review’. BMC Geriatr 17(1): 242.Google Scholar
Schuling, J., Gebben, H., Veehof, L. J., Haaijer-Ruskamp, F. M. (2012) ‘Deprescribing medication in very elderly patients with multimorbidity: The view of Dutch GPs. A qualitative study’. BMC Fam Pract 13(1): 56.Google Scholar
Holmes, H. M., Min, L. C., Yee, M., Varadhan, R., et al. (2013) ‘Rationalizing prescribing for older patients with multimorbidity: Considering time to benefit’. Drugs Aging 30(9): 655–66.Google Scholar
Gillespie, R., Mullan, J., Harrison, L. (2014) ‘Managing medications: The role of informal caregivers of older adults and people living with dementia. A review of the literature’. J Clin Nurs 23(23–4): 32963308.Google Scholar
Orlu-Gul, M., Raimi-Abraham, B., Jamieson, E., Wei, L., et al. (2014) ‘Public engagement workshop: How to improve medicines for older people?Int J Pharm 459(1–2): 65–9.Google Scholar
Maidment, I. D., Shaw, R. L., Killick, K., Damery, S., et al. (2016) ‘Improving the management of behaviour that challenges associated with dementia in care homes: Protocol for pharmacy–health psychology intervention feasibility study’. BMJ Open 6(3): e010279.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×